SI2343275T1 - Kristaliniäśna oblika optiäśnih enantiomerov modafinila - Google Patents

Kristaliniäśna oblika optiäśnih enantiomerov modafinila

Info

Publication number
SI2343275T1
SI2343275T1 SI200332281T SI200332281T SI2343275T1 SI 2343275 T1 SI2343275 T1 SI 2343275T1 SI 200332281 T SI200332281 T SI 200332281T SI 200332281 T SI200332281 T SI 200332281T SI 2343275 T1 SI2343275 T1 SI 2343275T1
Authority
SI
Slovenia
Prior art keywords
modafinil
crystalline form
optical enantiomers
enantiomers
optical
Prior art date
Application number
SI200332281T
Other languages
English (en)
Inventor
Olivier Neckebrock
Laurent Courvoisier
Stephanie Graf
Gilles Serrure
Gerard Coquerel
Sebastien Rose
Christine Besselievre
Franck Mallet
Langevelde Adriaan Jan Van
Pierre Leproust
Original Assignee
Teva Sante
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32406320&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2343275(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Sante filed Critical Teva Sante
Publication of SI2343275T1 publication Critical patent/SI2343275T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/06—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
SI200332281T 2002-12-20 2003-12-18 Kristaliniäśna oblika optiäśnih enantiomerov modafinila SI2343275T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0216412A FR2849029B1 (fr) 2002-12-20 2002-12-20 Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
EP11163602.3A EP2343275B1 (fr) 2002-12-20 2003-12-18 Forme cristalline des énantiomères optiques du modafinil.

Publications (1)

Publication Number Publication Date
SI2343275T1 true SI2343275T1 (sl) 2013-10-30

Family

ID=32406320

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200332281T SI2343275T1 (sl) 2002-12-20 2003-12-18 Kristaliniäśna oblika optiäśnih enantiomerov modafinila

Country Status (29)

Country Link
US (10) US7132570B2 (sl)
EP (6) EP2676952A3 (sl)
JP (2) JP4719471B2 (sl)
KR (1) KR101050565B1 (sl)
CN (5) CN100540533C (sl)
AR (1) AR042546A1 (sl)
AU (2) AU2003299349C1 (sl)
CA (2) CA2724305A1 (sl)
CL (2) CL2007002450A1 (sl)
CY (1) CY1114291T1 (sl)
DK (1) DK2343275T3 (sl)
EA (1) EA009592B1 (sl)
EG (1) EG24849A (sl)
ES (3) ES2627808T3 (sl)
FR (1) FR2849029B1 (sl)
HK (2) HK1192222A1 (sl)
IL (1) IL169205A (sl)
IS (1) IS7947A (sl)
MX (1) MXPA05006525A (sl)
MY (1) MY142926A (sl)
NO (1) NO335724B1 (sl)
NZ (2) NZ540733A (sl)
PL (1) PL377196A1 (sl)
PT (1) PT2343275E (sl)
SI (1) SI2343275T1 (sl)
TW (1) TWI344952B (sl)
UA (1) UA100964C2 (sl)
WO (1) WO2004060858A1 (sl)
ZA (1) ZA200504805B (sl)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
AU2003213719A1 (en) 2002-03-01 2003-09-16 Regents Of The University Of Michigan Multiple-component solid phases containing at least one active pharmaceutical ingredient
CA2489984A1 (en) 2002-06-21 2003-12-31 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
FR2849029B1 (fr) 2002-12-20 2005-03-18 Lafon Labor Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US7521553B2 (en) 2003-03-17 2009-04-21 Hetero Drugs Limited Crystalline forms of lamotrigine
WO2004082630A2 (en) * 2003-03-17 2004-09-30 Neurohealing Pharmaceuticals, Inc. High potency dopaminergic treatment of neurological impairment associated with brain injury
JP4842819B2 (ja) * 2003-09-04 2011-12-21 セフアロン・インコーポレーテツド モダフィニル組成物
US7368591B2 (en) 2003-09-19 2008-05-06 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
EP1516869A1 (en) 2003-09-19 2005-03-23 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
EP1718607A4 (en) * 2004-02-06 2008-05-28 Cephalon Inc COMPOSITIONS BASED ON MODAFINIL
US20090018202A1 (en) * 2004-02-06 2009-01-15 Cephalon, Inc. Modafinil compositions
EP2292213A1 (en) * 2004-02-06 2011-03-09 Cephalon, Inc. Compositions comprising a polymorphic form of armodafinil
MX2007000765A (es) 2004-07-20 2007-03-28 Warner Lambert Co Formas cristalinas de sal de calcio del acido (r-(r*, r*))-2- (4-fluorofenil)- beta,gama- dihidroxi-5- (1-metiletil)-3 -fenil-4-((fenilamino) (carbonil)-1ih -pirrol-1- heptanoico (2:1).
US20060086667A1 (en) * 2004-09-13 2006-04-27 Cephalon, Inc., U.S. Corporation Methods for the separation of enantiomeric sulfinylacetamides
EP1702915A1 (en) 2005-03-14 2006-09-20 Cephalon France Process for enantioselective synthesis of single enantiomers of thio-substituted arylmethanesulfinyl derivatives by asymmetric oxidation
US20090123545A1 (en) * 2005-07-21 2009-05-14 Ron Eyal S Rapid Onset and Short Term Modafinil Compositions and Methods of Use Thereof
US20070293702A1 (en) * 2006-02-21 2007-12-20 Viviana Braude Novel crystalline forms of armodafinil and preparation thereof
EP2159219A3 (en) 2006-03-01 2010-12-15 Teva Pharmaceutical Industries Ltd. An improved process for the preparation of armodafinil
BRPI0714173A2 (pt) * 2006-07-12 2012-12-25 Elan Pharma Int Ltd composiÇço nanoparticulada estÁvel,mÉtodos para preparar a composiÇço, para prevenir e/ou tratar estados de doenÇas, sintomas, sÍndromes e condiÇÕes do sistema nervoso central, para melhorar ou manter a biodisponibilidade de modafinil, e para tratar distérbio com base neurolàgica, composiÇço farmacÊutica, e forma de dosagem
DK2056811T3 (en) * 2006-08-14 2018-05-22 Neurohealing Pharmaceuticals Inc Modafinil-based treatment for premature ejaculation
US20080214862A1 (en) * 2006-12-06 2008-09-04 Ben-Zion Dolitzky Processes for preparing armodafinil intermediate
WO2008077127A2 (en) * 2006-12-19 2008-06-26 Lavin Thomas N Use of modafinil to treat restless leg syndrome
EP2155664A2 (en) * 2007-06-04 2010-02-24 Generics Ýuk¨Limited Novel process
WO2009024863A2 (en) * 2007-06-26 2009-02-26 Actavis Group Ptc Ehf Process for the preparation of modafinil enantiomers
US7960586B2 (en) * 2007-08-16 2011-06-14 Teva Pharmaceutical Industries Ltd. Purification of armodafinil
US20090082462A1 (en) * 2007-09-25 2009-03-26 Protia, Llc Deuterium-enriched armodafinil
US20090105346A1 (en) * 2007-10-02 2009-04-23 Alexandr Jegorov Novel crystalline forms of armodafinil and preparation thereof
WO2009090663A1 (en) * 2008-01-15 2009-07-23 Lupin Limited Novel crystalline polymorph of armodafinil and an improved process for preparation thereof
US20090325999A1 (en) * 2008-06-27 2009-12-31 Jie Du Personalized pharmaceutical kits, packaging and compositions for the treatment of allergic conditions
US20100036164A1 (en) * 2008-08-06 2010-02-11 Srinivas Areveli Preparation of armodafinil form i
EP2292306B1 (en) * 2009-09-02 2013-05-01 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for separation of racemic compound-forming chiral substances by a cyclic crystallization process and a crystallization device
WO2011061610A2 (en) * 2009-11-19 2011-05-26 Ranbaxy Laboratories Limited Processes for preparation of polymorphic forms of lacosamide
US20110224196A1 (en) * 2010-01-07 2011-09-15 Vivus, Inc. Treatment of obstructive sleep apnea syndrome with a combination of a carbonic anhydrase inhibitor and an additional active agent
DK2649187T3 (da) 2010-12-08 2018-01-29 Codexis Inc Biokatalysatorer og fremgangsmåder til syntesen af armodafinil
JP6116847B2 (ja) * 2012-10-01 2017-04-19 アムビト バイオサイエンシス コーポレーションＡｍｂｉｔ Ｂｉｏｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ シクロデキストリンとの混合体を含有する錠剤
US10466776B2 (en) * 2014-06-24 2019-11-05 Paypal, Inc. Surfacing related content based on user interaction with currently presented content
US10298825B2 (en) * 2014-07-23 2019-05-21 Orcam Technologies Ltd. Systems and methods for remembering held items and finding lost items using wearable camera systems
AU2015354040B2 (en) * 2014-11-27 2019-01-31 Gc Corporation Surface treatment agent for wax pattern and method of manufacturing dental prosthesis
WO2017064723A1 (en) * 2015-10-12 2017-04-20 Natco Pharma Ltd An improved process for the preparation of armodafinil

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1905990A (en) 1931-01-02 1933-04-25 Hoffmann La Roche Disubstituted carbamic acid esters of phenols containing a basic constituent
GB1197809A (en) 1968-02-13 1970-07-08 Inst Noguchi Method for Continuous Optical Resolution of Organic Racemates.
GB1584462A (en) * 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
FR2593809B1 (fr) * 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
FR2597864B1 (fr) 1986-04-28 1990-11-16 Lafon Labor Nouveaux derives de la n-((trimethoxy-2,4,6-benzoyl)-3 propyl) piperidine, leurs procedes de preparation et leur application en therapeutique
FR2626881B1 (fr) 1988-02-10 1990-07-27 Lafon Labor 1-(4-aminophenyl)-2-hexamethyleneiminopropanone, procede de preparation et utilisation en therapeutique
FR2663225B1 (fr) * 1990-06-14 1994-11-04 Lafon Labor Nouvelle utilisation du modafinil.
FR2671349B1 (fr) 1991-01-09 1993-04-23 Lafon Labor Nouveaux derives de 1,4-dihydropyridine, leur procede de preparation et composition therapeutique les contenant.
FR2710337B1 (fr) * 1993-09-23 1995-12-08 Gerard Coquerel Procédé de dédoublement de deux antipodes optiques par entraînement polythermique programmé et autoensemencé.
US6894171B1 (en) 1998-07-20 2005-05-17 Abbott Laboratories Polymorph of a pharmaceutical
CN1249932A (zh) 1999-09-29 2000-04-12 付俊昌 一种莫达芬尼及其光学对映体l及d异构体的新用途
JP2003519698A (ja) 2000-01-07 2003-06-24 トランスフォーム ファーマスーティカルズ，インコーポレイテッド 多様な固体形態のハイスループットでの形成、同定および分析
US20010036640A1 (en) 2000-04-25 2001-11-01 D'amico Kevin L. System and methods for the high throughput screening of polymorphs
US6492396B2 (en) * 2000-05-16 2002-12-10 Cephalon, Inc. Substituted thioacetamides
US6670358B2 (en) 2000-05-16 2003-12-30 Cephalon, Inc. Substituted thioacetamides
DE10025756C2 (de) * 2000-05-25 2003-02-20 Cognis Deutschland Gmbh Lösungsvermittler
PT1309547E (pt) * 2000-07-27 2007-03-30 Teva Pharma Modafinil cristalino e puro, e processo para a sua preparação
US6835307B2 (en) * 2000-08-04 2004-12-28 Battelle Memorial Institute Thermal water treatment
US6489363B2 (en) * 2000-10-11 2002-12-03 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
US6919378B2 (en) * 2000-10-11 2005-07-19 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
US6605636B2 (en) 2000-11-03 2003-08-12 Teva Pharmaceutical Industries Ltd. Atorvastatin hemi-calcium form VII
ES2281527T3 (es) * 2001-05-25 2007-10-01 Cephalon, Inc. Formulaciones farmaceuticas solidas que comprenden modafinilo.
JP2005502861A (ja) 2001-08-10 2005-01-27 サイミックス テクノロジーズ， インコーポレイテッド 事前処方物を作製および試験するための装置および方法ならびにそのためのシステム
EP1466166B2 (en) 2002-01-15 2013-05-01 Avantium International B.V. Method for performing powder diffraction analysis
US6875893B2 (en) * 2002-05-23 2005-04-05 Cephalon, Inc. Preparations of a sulfinyl acetamide
US7229644B2 (en) * 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
US20040048931A1 (en) * 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
DE60221052T2 (de) 2002-08-02 2007-11-08 Avantium International B.V. Vorrichtung und verfahren zur parallelen durchführung chemischer experimente, insbesondere kristallisationsexperimente
US6992219B2 (en) * 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms
JP4903385B2 (ja) 2002-12-06 2012-03-28 パーデュー・リサーチ・ファウンデーション 損傷した哺乳類神経組織を治療するためのピリジン類
FR2849029B1 (fr) 2002-12-20 2005-03-18 Lafon Labor Procede de preparation et formes cristallines des enantiomeres optiques du modafinil.
AU2004270238B2 (en) 2003-09-04 2010-07-29 Cephalon, Inc. Modafinil compositions
US7566805B2 (en) * 2003-09-04 2009-07-28 Cephalon, Inc. Modafinil compositions
US20090018202A1 (en) * 2004-02-06 2009-01-15 Cephalon, Inc. Modafinil compositions
EP1718607A4 (en) 2004-02-06 2008-05-28 Cephalon Inc COMPOSITIONS BASED ON MODAFINIL
CA2584246C (en) 2004-10-13 2011-08-09 Pharmacia & Upjohn Company Llc Crystalline forms of 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6h)-yl]-n-(2-hydroxyethyl)-4-methylbenzamide
US20090123545A1 (en) * 2005-07-21 2009-05-14 Ron Eyal S Rapid Onset and Short Term Modafinil Compositions and Methods of Use Thereof
US20070293702A1 (en) * 2006-02-21 2007-12-20 Viviana Braude Novel crystalline forms of armodafinil and preparation thereof
EP2159219A3 (en) 2006-03-01 2010-12-15 Teva Pharmaceutical Industries Ltd. An improved process for the preparation of armodafinil
EP2155664A2 (en) 2007-06-04 2010-02-24 Generics Ýuk¨Limited Novel process
WO2009024863A2 (en) 2007-06-26 2009-02-26 Actavis Group Ptc Ehf Process for the preparation of modafinil enantiomers
US7960586B2 (en) 2007-08-16 2011-06-14 Teva Pharmaceutical Industries Ltd. Purification of armodafinil
US20090105346A1 (en) * 2007-10-02 2009-04-23 Alexandr Jegorov Novel crystalline forms of armodafinil and preparation thereof
EP1911739A3 (en) * 2007-11-05 2008-09-17 Dipharma Francis S.r.l. Crystalline form of (S)-2-phenylethylammonium (R)-diphenyl-methanesulphinyl-acetate
WO2009090663A1 (en) 2008-01-15 2009-07-23 Lupin Limited Novel crystalline polymorph of armodafinil and an improved process for preparation thereof

Also Published As

Publication number Publication date
EG24849A (en) 2010-10-27
TW200419175A (en) 2004-10-01
US20060135621A1 (en) 2006-06-22
US20140031589A1 (en) 2014-01-30
FR2849029A1 (fr) 2004-06-25
CN100540533C (zh) 2009-09-16
TWI344952B (en) 2011-07-11
US20090281193A1 (en) 2009-11-12
EA200501016A1 (ru) 2005-12-29
CN101012189A (zh) 2007-08-08
ES2627808T3 (es) 2017-07-31
ZA200504805B (en) 2006-07-26
FR2849029B1 (fr) 2005-03-18
KR20050085847A (ko) 2005-08-29
EP2343275A3 (fr) 2011-08-17
AU2003299349B2 (en) 2010-06-03
HK1225371A1 (zh) 2017-09-08
UA100964C2 (ru) 2013-02-25
US20100048719A1 (en) 2010-02-25
EP2343275A2 (fr) 2011-07-13
CY1114291T1 (el) 2016-08-31
AU2003299349C1 (en) 2011-01-20
MY142926A (en) 2011-01-31
CN1751021A (zh) 2006-03-22
AU2010212462A1 (en) 2010-09-16
PL377196A1 (pl) 2006-01-23
JP4719471B2 (ja) 2011-07-06
JP2006511588A (ja) 2006-04-06
CL2007002450A1 (es) 2009-01-16
US20090281192A1 (en) 2009-11-12
EP2679578A2 (fr) 2014-01-01
NZ571235A (en) 2010-01-29
WO2004060858A1 (fr) 2004-07-22
AU2003299349A8 (en) 2004-07-29
EP1572635B1 (fr) 2017-04-12
US20060241320A1 (en) 2006-10-26
EP2679578B1 (fr) 2016-03-09
US20100048718A1 (en) 2010-02-25
CA2510096C (fr) 2011-02-22
EP2679578A3 (fr) 2014-03-19
AU2003299349A1 (en) 2004-07-29
NO20052912D0 (no) 2005-06-15
CN106065007A (zh) 2016-11-02
US20100048720A1 (en) 2010-02-25
US7132570B2 (en) 2006-11-07
ES2575018T3 (es) 2016-06-23
MXPA05006525A (es) 2005-12-05
EP1572635A1 (fr) 2005-09-14
US20130274521A1 (en) 2013-10-17
US20100022653A1 (en) 2010-01-28
CN101012189B (zh) 2013-03-13
AR042546A1 (es) 2005-06-22
EP2676952A2 (fr) 2013-12-25
JP2011102330A (ja) 2011-05-26
KR101050565B1 (ko) 2011-07-19
BRPI0316916A8 (pt) 2015-09-22
EA009592B1 (ru) 2008-02-28
CL2016002640A1 (es) 2017-03-24
EP2679577A3 (fr) 2014-02-12
DK2343275T3 (da) 2013-07-01
US9382200B2 (en) 2016-07-05
CA2724305A1 (fr) 2004-07-22
EP2679576A2 (fr) 2014-01-01
BR0316916A (pt) 2005-10-18
EP2343275B1 (fr) 2013-04-24
NO20052912L (no) 2005-07-19
EP2676952A3 (fr) 2014-02-12
US8975442B2 (en) 2015-03-10
EP2679577A2 (fr) 2014-01-01
JP5497680B2 (ja) 2014-05-21
PT2343275E (pt) 2013-07-30
CN101654423A (zh) 2010-02-24
US8729305B2 (en) 2014-05-20
IS7947A (is) 2005-07-19
HK1192222A1 (zh) 2014-08-15
CN101914044A (zh) 2010-12-15
ES2425023T3 (es) 2013-10-10
NO335724B1 (no) 2015-02-02
EP2679576A3 (fr) 2014-02-12
NZ540733A (en) 2008-10-31
CA2510096A1 (fr) 2004-07-22
IL169205A (en) 2013-11-28

Similar Documents

Publication Publication Date Title
SI2343275T1 (sl) Kristaliniäśna oblika optiäśnih enantiomerov modafinila
AU2003250690A1 (en) Auto-characterization of optical devices
AU2003248651A8 (en) Optical metrology of single features
IL209319A0 (en) Substituted tetracycline compounds for the treatment of malaria
HK1108157A1 (en) Intermediates for the preparation of dioxane-2-alkyl carbamates
EP1517944A4 (en) IMPROVEMENT TO LOW LOSS OPTICAL MATERIAL
AP1955A (en) Novel crystalline modification of the anhydrate ofboscalid
GB0315130D0 (en) Structure of light box assembly
GB2390424B (en) Optical controls
HK1075119A1 (en) Optical disk
AU2003276026A1 (en) Bicalutamide forms
AU2003264933A1 (en) Optical micro-actuator
GB2398029B (en) Production of disc components
EP1486817A4 (en) METHOD FOR MANUFACTURING AN OPTICAL MODULATOR
AU2003242867A1 (en) Process for the synthesis of mosapride
HK1158171A1 (en) Crystalline form of the optical enantiomers of modafinil
AU2003224495A1 (en) Process for the preparation of enantiomerically enriched compounds
EP1505582A4 (en) OPTICAL HEAD
AU2003248597A1 (en) The purification of 2-methoxy-5-trifluoromethoxybenzaldehyde
EP1528547A4 (en) OPTICAL DATA CARRIER
GB0215794D0 (en) Optical characterisation of materials
AU2003231733A8 (en) Optical disc construction
AU2003300974A8 (en) Process for the separation of enantiomers
GB0224405D0 (en) Optical component manufacture
AU2003232212A1 (en) Regulation of erythrocyte apoptosis